{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bacterial-vaginosis/management/women-who-are-not-pregnant/","result":{"pageContext":{"chapter":{"id":"c43aecb1-cb55-5433-a0ce-81481bc43060","slug":"women-who-are-not-pregnant","fullItemName":"Scenario: Women who are not pregnant","depth":2,"htmlHeader":"<!-- begin field 484af769-6c65-43cc-84c3-b44d0bb8b713 --><h2>Scenario: Bacterial vaginosis in women who are not pregnant</h2><!-- end field 484af769-6c65-43cc-84c3-b44d0bb8b713 -->","summary":"Covers the management of suspected bacterial vaginosis (BV) in women who are not pregnant.","htmlStringContent":"<!-- begin item b1e6517a-c1fa-43d1-a303-e540ee3959e9 --><!-- begin field 3300013b-6f17-4b98-a08a-acbc015a9464 --><p>From age 12 years onwards (Female).</p><!-- end field 3300013b-6f17-4b98-a08a-acbc015a9464 --><!-- end item b1e6517a-c1fa-43d1-a303-e540ee3959e9 -->","topic":{"id":"865cdea2-9043-57ef-8b25-031205cdd37d","topicId":"afc41d7e-87dd-41b7-bbc7-b86b9168703c","topicName":"Bacterial vaginosis","slug":"bacterial-vaginosis","lastRevised":"Last revised in October 2018","chapters":[{"id":"f7fe1c4f-d424-53b7-9e1d-2e724534b550","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ff6b3e14-7f5b-50db-8eee-ad227bf399c7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9d2f35ec-215f-5ee1-b407-2c5b68e931b0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"06809c66-f539-5454-a18a-ff951a80494b","slug":"changes","fullItemName":"Changes"},{"id":"0872ed37-dd2a-58ae-ba58-ecd7dd9c964e","slug":"update","fullItemName":"Update"}]},{"id":"b96f10d4-f421-527a-bcaf-8e5e46afb0b5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7b27492c-f7b2-5bdf-8be5-596f1ad99050","slug":"goals","fullItemName":"Goals"},{"id":"8b94b860-815d-522b-b4fe-461ef978443a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b1dc3d72-ac27-5757-be13-e2015daa0798","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8cef0513-bbd8-5919-961e-a28c7cfdd421","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7bc7f747-27e8-5daa-9d10-380bdcd0f2e2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e58af854-9d1b-51ce-a49a-83df8540a21a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d6cf6c66-7d92-5d41-933f-a9a879fa36d4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ebdd3d77-69b1-523d-a4ac-4de1bd53fcfe","slug":"definition","fullItemName":"Definition"},{"id":"7f17b28f-8990-5777-98b2-0b0a488d883f","slug":"contributing-factors","fullItemName":"Contributing factors"},{"id":"276cab7f-4264-59d9-8986-e8de8d64e45e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9a592036-9b11-587b-8576-77aac8d2b2ef","slug":"complications","fullItemName":"Complications"}]},{"id":"a011fb71-c488-53bd-b5ca-10e92c77583a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b250f8fd-847f-5844-a2d6-32014c81a438","slug":"assessment","fullItemName":"Assessment"},{"id":"e655909b-34b2-55ce-8897-68a2131e1a0c","slug":"examination-investigations","fullItemName":"Examination and investigations"},{"id":"5cc72fff-2222-558d-815e-907a5a25c2ef","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0ae8498b-179a-5f9f-8ece-c5004a1ed196","fullItemName":"Management","slug":"management","subChapters":[{"id":"c43aecb1-cb55-5433-a0ce-81481bc43060","slug":"women-who-are-not-pregnant","fullItemName":"Scenario: Women who are not pregnant"},{"id":"e17bea46-46ca-5a5a-8f23-6d2541ef18b2","slug":"women-who-are-pregnant","fullItemName":"Scenario: Women who are pregnant"}]},{"id":"ff8ddbda-8b29-5d43-ad60-5aeb14b120d3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"39735e82-4c9f-5aa2-97c7-1496f80b7c1f","slug":"oral-metronidazole","fullItemName":"Oral metronidazole"},{"id":"5eef68f3-35a3-5708-a789-014713e8af64","slug":"intravaginal-metronidazole","fullItemName":"Intravaginal metronidazole"},{"id":"ecf84ab7-5f32-5135-a8c2-b302e217480a","slug":"intravaginal-clindamycin","fullItemName":"Intravaginal clindamycin"}]},{"id":"dbca4e81-4cb5-5161-95af-5aed06ab1909","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bab503ee-9268-578a-957b-b6f29998ba50","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a1542e98-52d3-5650-8f50-017cdafb6bb1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dddaaa3b-0dea-5b97-a24a-18f6f861a9b4","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"305419c2-e2ba-51d7-b38f-9d98fdb980ed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b64a9957-d6e0-5d40-9465-e092bfde8548","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"748d8b76-5aee-5fe6-898a-43bbffd5751b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efc1492f-d327-53ae-b257-f0f17e740c27","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0ae8498b-179a-5f9f-8ece-c5004a1ed196","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"b0cc66c6-e14c-5323-ad1b-ec05d9a71200","slug":"managing-bacterial-vaginosis","fullItemName":"Managing bacterial vaginosis","depth":3,"htmlHeader":"<!-- begin field 5342c006-d542-447d-9b8e-2ec3ea2cfb97 --><h3>How should I treat a woman with bacterial vaginosis who is not pregnant?</h3><!-- end field 5342c006-d542-447d-9b8e-2ec3ea2cfb97 -->","summary":null,"htmlStringContent":"<!-- begin item 255dadd6-bd1d-4179-9a7d-6a634aeb01c5 --><!-- begin field 8caa101f-3877-4d1d-9092-a5003224442e --><ul><li><strong>If the woman is asymptomatic, </strong>treatment is not usually required, unless she is undergoing termination of pregnancy.</li><li><strong>If the woman is symptomatic:</strong><ul><li>Advise that, where possible, she should reduce exposure to <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/background-information/contributing-factors/\"> contributing factors</a>, such as vaginal douching and the use of antiseptics, bubble baths, or shampoos in the bath.</li><li>Prescribe oral metronidazole 400 mg twice a day for 5 to 7 days. <ul><li>If adherence to treatment is an issue, a single oral dose of 2 g may be used, if appropriate. </li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/prescribing-information/oral-metronidazole/\">Oral metronidazole</a> for prescribing information on this treatment, including contraindications and cautions, adverse effects, and possible drug interactions. </li></ul></li><li>If the woman prefers topical treatment or cannot tolerate oral metronidazole:<ul><li>Prescribe intravaginal metronidazole gel 0.75% once a day for 5 days (off-label for women aged younger than 18 years) or intravaginal clindamycin cream 2% once a day for 7 days.</li><li>See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/prescribing-information/intravaginal-metronidazole/\">intravaginal metronidazole</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/prescribing-information/intravaginal-clindamycin/\">Intravaginal clindamycin</a> for prescribing information on these treatments, including contraindications and cautions, adverse effects, and possible drug interactions. </li></ul></li><li>Oral clindamycin and oral tinidazole are alternatives but are less preferred.</li><li>A test of cure is not required if symptoms resolve. If symptoms persist or recur,<strong> </strong>see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/management/women-who-are-not-pregnant/#managing-persistent-or-recurrent-symptoms\"> Managing persistent or recurrent symptoms</a> for further information.</li></ul></li></ul><!-- end field 8caa101f-3877-4d1d-9092-a5003224442e --><!-- end item 255dadd6-bd1d-4179-9a7d-6a634aeb01c5 -->","subChapters":[{"id":"bd0bfe50-a6d3-52ac-81a1-ddae06b7124b","slug":"basis-for-recommendation-065","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 22ba637b-aa22-46d5-bf18-d8dca7cb301c --><h4>Basis for recommendation</h4><!-- end field 22ba637b-aa22-46d5-bf18-d8dca7cb301c -->","summary":null,"htmlStringContent":"<!-- begin item 06525cc5-58a6-4152-aa2c-8d3d491042f4 --><!-- begin field f0e88855-15db-45ba-ae30-ab7288b17748 --><p>These recommendations are largely based on the <em>UK national guideline for the management of bacterial vaginosis </em>published by the British Association for Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BASHH, 2012</a>]<em>,</em> <em>Sexually Transmitted Infections in Primary Care 2013 (RCGP/BASHH) </em>published on behalf of the Royal College of General Practitioners (RCGP) and BASHH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Lazaro, 2013</a>], <em>Management and laboratory diagnosis of Abnormal Vaginal Discharge: Quick Reference Guide for Primary Care </em>published by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">PHE, 2013</a>], and the <em>2018</em> <em>European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge </em>published on behalf of<em> </em>the International Union against Sexually Transmitted Infections (IUSTI) and the World Health Organization (WHO) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>].</p><h5>Managing asymptomatic women</h5><ul><li>BASHH does not recommend treatment of asymptomatic non-pregnant women with an incidental finding of bacterial vaginosis (BV), but states that treatment is indicated for women undergoing some surgical procedures (although the procedures are not specified) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BASHH, 2012</a>].</li><li>Evidence from three randomized controlled trials (RCTs) suggests that treating BV with either metronidazole or clindamycin cream before termination of pregnancy may reduce the incidence of subsequent genital tract infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Larsson et al, 1992</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Larsson et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Crowley et al, 2001</a>].<ul><li>Expert opinion is divided over treatment of BV in asymptomatic women before other invasive procedures, such as intrauterine device (IUD) insertion or endometrial biopsy. Some expert reviewers of this CKS topic stated that they would consider treatment of BV in asymptomatic women in these situations; however, current evidence does not support this approach.</li></ul></li></ul><h5>Antibiotic choices</h5><ul><li>Metronidazole is licensed for the prophylaxis and treatment of infections in which anaerobic bacteria have been identified or are suspected to be the cause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">ABPI, 2017</a>], such as BV. It is a well established treatment, usually well tolerated, and inexpensive.</li><li>Intravaginal clindamycin is licensed for the treatment of BV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">ABPI, 2018</a>].</li><li>Evidence from a Cochrane systematic review (search date: December 2007) suggests that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Oduyebo et al, 2009</a>]:<ul><li>Oral metronidazole and clindamycin (tablets, ovules, and cream) are equally effective in treating BV.</li><li>Both intravaginal clindamycin and intravaginal metronidazole are more effective than placebo in treating BV.</li><li>There are no additional clinical benefits in extending the treatment course with metronidazole beyond 7 days.</li></ul></li><li>Oral clindamycin is not widely recommended in primary care because of an increased risk of pseudomembranous colitis associated with its use.</li><li>Oral tinidazole has been less well studied than metronidazole in the treatment of BV.</li></ul><h5>Test of cure </h5><ul><li>The information on test of cure is based on the BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BASHH, 2012</a>] and the IUSTI/WHO guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>].</li></ul><!-- end field f0e88855-15db-45ba-ae30-ab7288b17748 --><!-- end item 06525cc5-58a6-4152-aa2c-8d3d491042f4 -->","subChapters":[]}]},{"id":"114afc5a-8fba-54e4-af50-d757fe6bbdd1","slug":"managing-persistent-or-recurrent-symptoms","fullItemName":"Managing persistent or recurrent symptoms","depth":3,"htmlHeader":"<!-- begin field 3360dade-538b-405c-bb29-f04cd6c91602 --><h3>How should I manage a woman with persistent or recurrent symptoms?</h3><!-- end field 3360dade-538b-405c-bb29-f04cd6c91602 -->","summary":null,"htmlStringContent":"<!-- begin item da9b90d5-af21-4c7f-9fd0-8f823e675d99 --><!-- begin field eb4c5e64-02f4-4ed8-af71-772dd40d63d5 --><ul><li><strong>If symptoms persist:</strong><ul><li>Check that the<strong> </strong><a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/management/women-who-are-not-pregnant/#managing-bacterial-vaginosis\">initial treatment</a><strong> </strong>was adhered to.</li><li>Reconsider the <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/diagnosis/examination-investigations/\">diagnosis</a>. Perform a speculum examination and take swabs for culture. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/diagnosis/examination-investigations/\">Examination and investigations</a> for more information.</li><li>Enquire about continued exposure to <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/background-information/contributing-factors/\"> contributing factors</a>, such as vaginal douching and the use of antiseptics, bubble baths, or shampoos in the bath.<ul><li>For persistent bacterial vaginosis (BV) in women with an intrauterine contraceptive device, consider removing the device and advising the use of an alternative form of contraception. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for advice on assessing women for various methods of contraception.    </li></ul></li><li>Ensure that the current episode is adequately managed.<ul><li>Prescribe an <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/management/women-who-are-not-pregnant/#managing-bacterial-vaginosis\">alternative treatment</a>, for example if a single 2 g dose of metronidazole or an intravaginal preparation was used previously, prescribe oral metronidazole 400 mg twice a day for 7 days.</li></ul></li><li>In the unlikely event that a woman with confirmed BV has not responded to a 7-day course of oral metronidazole, consider discussing with a gynaecologist or genito-urinary medicine (GUM) specialist regarding further treatment.</li><li>Routine screening and treatment of male partners is not indicated, but consider testing and treating the female partner in a same-sex relationship.</li></ul></li><li><strong>If symptoms recur:</strong><ul><li>Advise the woman that recurrence of symptoms is common.</li><li>Reconsider the <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/diagnosis/examination-investigations/\">diagnosis</a>. Perform a speculum examination and take swabs for culture. Further examination and investigations may not be necessary if a previous episode of recognizably similar symptoms was previously diagnosed to be BV and:<ul><li>Symptoms and signs cleared after antibiotic treatment.</li><li>Symptoms, signs, and microbiological evidence from swabs of other conditions causing vaginal discharge were absent.</li><li>Characteristic symptoms and signs of BV were present.</li></ul></li><li>Enquire about continued exposure to <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/background-information/contributing-factors/\"> contributing factors</a>, such as vaginal douching and the use of antiseptics, bubble baths, or shampoos in the bath.</li><li>Treat the current episode with a 7-day course of oral metronidazole 400 mg twice a day.</li><li>If the diagnosis is confirmed and symptoms recur frequently (at least four times a year) despite adequate management in primary care, and symptoms are adversely affecting the woman, consider prescribing metronidazole vaginal gel as suppressive treatment (off-label use) if experienced in treating recurrent BV in primary care. Otherwise, discuss management with a gynaecologist or GUM specialist.</li></ul></li></ul><!-- end field eb4c5e64-02f4-4ed8-af71-772dd40d63d5 --><!-- end item da9b90d5-af21-4c7f-9fd0-8f823e675d99 -->","subChapters":[{"id":"16f975e1-1924-5ae8-b56e-5a28eb5c8c07","slug":"basis-for-recommendation-6b3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f6af5c2a-4891-45d3-a6b5-3ceae66ba7ca --><h4>Basis for recommendation</h4><!-- end field f6af5c2a-4891-45d3-a6b5-3ceae66ba7ca -->","summary":null,"htmlStringContent":"<!-- begin item 6b35af5e-77d5-4c86-922c-4461a58befa8 --><!-- begin field ffb98a61-49f2-4430-8ce6-58ed86117abe --><p>These recommendations are largely based on the <em>UK national guideline for the management of bacterial vaginosis </em>published by the British Association for Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BASHH, 2012</a>]<em>,</em> <em>Sexually Transmitted Infections in Primary Care 2013 (RCGP/BASHH) </em>published on behalf of the Royal College of General Practitioners (RCGP) and BASHH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Lazaro, 2013</a>], <em>Management and laboratory diagnosis of Abnormal Vaginal Discharge: Quick Reference Guide for Primary Care </em>published by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">PHE, 2013</a>], and the <em>2018</em> <em>European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge </em>published on behalf of<em> </em>the International Union against Sexually Transmitted Infections (IUSTI) and the World Health Organization (WHO) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>].</p><h5>Managing persistent symptoms</h5><ul><li>CKS found no evidence regarding treatment options if initial treatment is unsuccessful. These recommendations are largely pragmatic, based on what CKS considers to be good clinical practice. Persistent symptoms are likely to be due to poor adherence to treatment, misdiagnosis, or continued exposure to contributing factors. </li><li>Small studies identified in the IUSTI/WHO guideline have reported an increased incidence of bacterial vaginosis (BV) with the copper intrauterine device (IUD), but it is not known what effect, if any, progestogen-containing levonorgestrel intrauterine system has on BV incidence<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>]. The recommendation to consider IUD removal in a woman with persistent BV is pragmatic and is supported by previous reviewers of this CKS topic. </li><li>Routine screening and treatment of male partners is not indicated because no reduction in relapse rate was reported from studies in which male partners of women with BV were treated with metronidazole, tinidazole, or clindamycin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BASHH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>].</li><li>Women who have sex with women share similar lactobacillary types, are more likely to have concordant vaginal flora patterns, and are at increased risk for BV. Therefore, consideration should be given to testing and treating female partners of women with BV, although there is no evidence that this will reduce BV recurrences [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>].</li></ul><h5>Managing recurrent symptoms</h5><ul><li>Recurrence of BV is common. Evidence from a longitudinal study identified in the IUSTI/WHO guideline showed that following treatment of BV with oral metronidazole for 7 days, reported recurrence rates were 23% at 1 month, 43% at 3 months, and 58% at 12 months<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>]. </li><li>There are few published studies evaluating the optimal treatment approach in women with frequent recurrences of BV. The recommendations to check adherence to initial treatment, reconsider the diagnosis of BV, and advise against continued exposure to contributing factors, where possible, are pragmatic.<ul><li>BV is associated with smoking and vaginal douching, but there is no evidence that stopping these reduces BV<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>]. </li><li>Recurrence of BV is associated with new or multiple male partners and having had a female partner.</li></ul></li><li>A number of studies identified in the IUSTI/WHO guideline evaluated intravaginal and oral treatments to reduce BV recurrence<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>]:<ul><li>A placebo-controlled trial assessed the effect of monthly oral treatment (metronidazole 2g plus fluconazole 150mg) compared with placebo for 12 months and reported a reduced incidence of BV.</li><li>A second placebo-controlled trial assessed the effect of twice weekly metronidazole vaginal gel compared with placebo for 16 weeks and reported a significant reduction in BV recurrence. However, episodes of candidosis were common with metronidazole gel.</li><li>Based on the evidence, the guideline development group of the IUSTI/WHO guideline recommends that the current best treatment for persistent and recurrent BV in women is intravaginal metronidazole. <ul><li>Previous expert reviewers of this CKS topic agreed that for women with recurrent BV in whom the symptomatic episode has been adequately treated, intravaginal metronidazole may be beneficial as suppressive treatment. However, the use of metronidazole gel for this indication is off-label, evidence is lacking, and practice varies widely in terms of frequency and duration of treatment (depending on the severity of symptoms and whether recurrence is associated with the menstrual cycle). For this reason, CKS recommends discussing suppressive treatment with a specialist, unless the primary care practitioner is experienced in treating recurrent BV.</li></ul></li></ul></li></ul><!-- end field ffb98a61-49f2-4430-8ce6-58ed86117abe --><!-- end item 6b35af5e-77d5-4c86-922c-4461a58befa8 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}